Recruiting studies: Low Risk Myelodysplastic Syndromes

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS
Phase 3 · 179 location(s) · Takeda · NCT06499285 Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life in Lower Risk MDS
Phase N/A · 1 location(s) · Fundación para la Investigación Biosanitaria del Principado · NCT06614595 Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Phase 1/Phase 2 · 15 location(s) · Rigel Pharmaceuticals · NCT05308264 Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Phase N/A · 7 location(s) · Dana-Farber Cancer Institute · NCT02269592 Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions
NA · 2 location(s) · Rigshospitalet, Denmark · NCT06773871 Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
NA · 3 location(s) · Mayo Clinic · NCT02958462 A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Phase 2 · 39 location(s) · GlaxoSmithKline · NCT06847867 Combining Active and Passive DNA Hypomethylation
Phase 2 · 10 location(s) · Kirsten Grønbæk · NCT03999723 Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06046313 A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Lo
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04239157 Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (
Phase 2 · 1 location(s) · Hannah Choe, MD · NCT07249346 A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05365035 Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
Phase 1 · 5 location(s) · Clinical Hub for Interventional Research (CHOIR) · NCT05636514 Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
Phase 1 · 3 location(s) · Groupe Francophone des Myelodysplasies · NCT06670222 Oral-ATO for TP53-mutated Myeloid Malignancies
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06778187 A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes
Phase 2 · 20 location(s) · Takeda · NCT07319845 Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01515527 FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Montefiore Medical Center · NCT07283094 A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myel
Phase 3 · 156 location(s) · Takeda · NCT07422480 A Study to Evaluate the MNV-201 in Patients With Low Risk MDS
Phase 1 · 1 location(s) · Minovia Therapeutics Ltd. · NCT06465160 Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Phase 2 · 3 location(s) · Montefiore Medical Center · NCT05184842 A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Phase 1/Phase 2 · 1 location(s) · Lixte Biotechnology Holdings, Inc. · NCT03886662 A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS
Phase 2 · 47 location(s) · Takeda · NCT04419649 Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples
Phase N/A · 1 location(s) · Josep Carreras Leukaemia Research Institute · NCT04251078 A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
Phase 2 · 1 location(s) · Pharmacosmos A/S · NCT05693909 Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
Phase 2 · 22 location(s) · University of Leipzig · NCT05384691 Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosi
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01624805 Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk M
Phase 2 · 2 location(s) · University of Southern California · NCT06063486

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.